4th November, 2026

To,
The Secretary,
Bombay Stock Exchange Ltd (BSE)
Phiroze Jheejheebhoy Towers,
Dalal Street,
Mumbai - 400 001.
Scrip Code - 543308
ISIN: INE967H01025

To,
The Secretary,
National Stock Exchange (NSE),
Exchange Plaza,
5th Floor Plot No.C/1, 'G' Block
Bandra - Kurla Complex
Mumbai - 400 051.
Symbol - KIMS

Dear Sir/ Madam

Sub: Monitoring Agency Report for the quarter ended September 30, 2026

Ref: Funds raised through Qualified Institutional Placement.

Pursuant to Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Regulation 162A(4) of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, the Monitoring Agency Report for the quarter ended on 30th September, 2026, issued by CARE Ratings Limited, duly reviewed by the Audit Committee of the Company is enclosed herewith.

Kindly take the above on your records.

Thanking You,

Yours truly

For Krishna Institute of Medical Sciences Limited

NAGAJAYANTHI JUTTUR RAGHAVENDRA DAS
Digitally signed by NAGAJAYANTHI JUTTUR RAGHAVENDRA DAS
Date: 2026.11.04 20:39:25 +05'30'

Nagajayanthi J. R
Company Secretary and Compliance Officer

No. CARE/HRO/GEN/2026-27/1025

The Board of Directors
Shri B. Bhaskara Rao
Managing Director
Krishna Institute of Medical Sciences Limited
D.No. 1-8-31/1,
Minister Road,
Secunderabad
Telangana - 500003

November 04, 2026

Dear Sir,

Monitoring Agency Report for the quarter ended September 30, 2026 in relation to the QIP issue of Krishna Institute of Medical Sciences Limited ("the Company" or "KIMS")

We write in our capacity of Monitoring Agency for the QIP issue for the amount aggregating to Rs. 1,500 crores of the Company and refer to our duties cast under 173A of the Securities & Exchange Board of India (Issue of Capital & Disclosure Requirements) Regulations, amended from time to time.

In this connection, we are enclosing the Monitoring Agency Report for the quarter ended September 30, 2026 as per aforesaid SEBI Regulations and Monitoring Agency Agreement dated June 16, 2026.

Request you to kindly take the same on records.

Thanking you,
Yours faithfully,

Pritesh Rathi
Associate Director
Pritesh.Rathi@careedge.in

CARE Ratings Limited

Report of the Monitoring Agency
Name of the issuer: Krishna Institute of Medical Sciences Ltd
For quarter ended: September 30, 2026
Name of the Monitoring Agency: CARE Ratings Limited
(a) Deviation from the objects: Nil
(b) Range of Deviation: Nil

Declaration:

We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013.

The MA or its affiliates may have credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit related analyses. We confirm that there is no conflict of interest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer, or while undertaking credit rating or other commercial transactions with the entity.

We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where applicable. There are certain sections of the report under the title "Comments of the Board of Directors", that shall be captured by the Issuer's Management / Audit Committee of the Board of Directors subsequent to the MA submitting their report to the issuer and before dissemination of the report through stock exchanges. These sections have not been reviewed by the MA, and the MA takes no responsibility for such comments of the issuer's Management/Board.



Signature:
Name and designation of the Authorized Signatory: Pritesh Rathi
Designation of Authorized person/Signing Authority: Associate Director

CARE Ratings Limited

401, Ashoka Scintilla, 3-6-520, Himayat Nagar,
Hyderabad - 500 029
Phone: +91-40-4010 2030

Corporate Office :4th Floor, Godrej Coliseum,
Somaiya Hospital Road, Off Eastern Express
Highway, Sion (E), Mumbai - 400 022
Phone: +91-22-6754 3456 • www.careedge.in

1) Issuer Details:

Name of the issuer	: Krishna Institute of Medical Sciences Limited
Name of the promoter	: Mr. Bhaskara Rao Bollineni, Mrs. Rajyasri Bollineni, Mr. Abhinay Bollineni and Bluebridge Capital Private Limited
Industry/sector to which it belongs	: Healthcare

2) Issue Details

Issue Period	: June 16, 2026 to June 19, 2026
Type of issue (public/rights)	: QIP
Type of specified securities	: Shares
IPO Grading, if any	: NA
Issue size (in crore)	: ₹1,500 crore

3) Details of the arrangement made to ensure the monitoring of issue proceeds:

Particulars	Reply	Source of information / certifications considered by Monitoring Agency for preparation of report	Comments of the Monitoring Agency	Comments of the Board of Directors
Whether all utilization is as per the disclosures in the Offer Document?	Yes	Chartered Accountant certificate*, utilization certificate from the management^, Bank statements and Loan account statements.	As per the placement document, the net proceeds of ₹1,476.45 crore are to be utilised by FY27. Till Q2FY27, the company has utilised ₹1,311.81 crores.	No comments received
Whether shareholder approval has been obtained in case of material deviations# from expenditures disclosed in the Offer Document?	No material deviation. Hence, not applicable	As confirmed by the issuer's management	Nil	No comments received
Whether the means of finance for the disclosed objects of the issue have changed?	No	As confirmed by the issuer's management	Nil	No comments received
Is there any major deviation observed over the earlier monitoring agency reports?	No	Q1FY27 MA report	Nil	No comments received
Whether all Government/statutory approvals related to the object(s) have been obtained?	Not applicable	Confirmation from management	Nil	No comments received
Whether all arrangements pertaining to technical assistance/collaboration are in operation?	Not applicable	Confirmation from management	Nil	No comments received
Are there any favorable/unfavorable events affecting the viability of these object(s)?	No major events	Confirmation from management	Nil	No comments received
Is there any other relevant information that may materially affect the decision making of the investors?	No	Confirmation from management	For utilisation towards general corporate purposes (GCP), the proceeds from the QIP were transferred into the company's and subsidiary companies' current accounts. As these accounts are also used for routine business transactions, the monitored proceeds were commingled with regular business funds.	No comments received

*Chartered Accountant certificate from B. Naga Bhushan & Co dated October 22, 2026.
^A document dated October 23, 2026, presenting the utilization of funds certified by CFO, Mr. Sachin Ashok Salvi.

#Where material deviation may be defined to mean:
a) Deviation in the objects or purposes for which the funds have been raised
b) Deviation in the amount of funds actually utilized by more than 10% of the amount projected in the placement documents.

4) Details of objects to be monitored:

(i) Cost of objects –

Sr. No	Item Head	Source of information / certifications considered by Monitoring Agency for preparation of report	Original cost (as per the Offer Document) in Rs. Crore	Revised Cost in Rs. Crore	Comments of the Monitoring Agency	Comments of the Board of Directors		
						Reason for cost revision	Proposed financing option	Particulars of -firm arrangements made
1	Repayment and/or prepayment of certain outstanding borrowings, in full or part, availed by KIMS	Chartered Accountant certificate*, utilization certificate from the management^ and placement document	910.00	-	Nil	No comments received	No comments received	No comments received
2	Investment into certain Subsidiaries, namely Chalasani Hospitals Pvt Ltd, KIMS Hospitals Pvt Ltd and KIMS Hospital Bengaluru Pvt Ltd, for repayment or prepayment, in full or in part, of certain outstanding borrowings availed by such Subsidiaries		215.00	-	Nil	No comments received	No comments received	No comments received
3	General Corporate Purpose		351.45	-	Nil	No comments received	No comments received	No comments received

4	Issue Expenses		23.55	-	Nil	No comments received	No comments received	No comments received
Total			**1,500.00**					

*Chartered Accountant certificate from B. Naga Bhushan & Co dated October 22, 2026.

^A document dated October 23, 2026, presenting the utilization of funds certified by CFO, Mr. Sachin Ashok Salvi.

(ii) Progress in the objects –

Sr. No	Item Head	Source of information / certifications considered by Monitoring Agency for preparation of report	Amount as proposed in the Offer Document in Rs. Crore	Amount utilised in Rs. Crore			Total unutilised amount in Rs. crore	Comments of the Monitoring Agency	Comments of the Board of Directors	
				As at beginning of the quarter in Rs. Crore	During the quarter in Rs. Crore	At the end of the quarter in Rs. Crore			Reasons for idle funds	Proposed course of action
1	Repayment and/or prepayment of certain outstanding borrowings, in full or part, availed by KIMS	Chartered Accountant certificate*, utilization certificate from the management^, Bank statements and Loan account statements.	910.00	910.00	-	910.00	Nil	During the previous quarter (April to June 2026), the company had fully utilised ₹910 crores allocated towards this object.	No comments received	No comments received
2	Investment into certain Subsidiaries, namely Chalasani Hospitals Pvt Ltd, KIMS Hospitals Pvt Ltd and KIMS Hospital Bengaluru Pvt Ltd, for repayment or prepayment, in full or in part, of certain outstanding		215.00	130.00	85.00	215.00	Nil	During the previous quarter (April to June 2026), the company has utilised ₹130 crores towards investment in subsidiaries for repayment of subsidiaries' borrowings. During the quarter (July to September 2026), the	No comments received	No comments received

Sr. No	Item Head	Source of information / certifications considered by Monitoring Agency for preparation of report	Amount as proposed in the Offer Document in Rs. Crore	Amount utilised in Rs. Crore			Total unutilised amount in Rs. crore	Comments of the Monitoring Agency	Comments of the Board of Directors	
				As at beginning of the quarter in Rs. Crore	During the quarter in Rs. Crore	At the end of the quarter in Rs. Crore			Reasons for idle funds	Proposed course of action
	borrowings availed by such Subsidiaries							company has further utilised ₹85 crores towards investment in subsidiaries for repayment of subsidiaries' borrowings. Out of this ₹65 crore was utilised for KIMS Hospitals Private Limited and balance ₹20 crores was for KIMS Hospital Bengaluru Private Limited.		
3	General Corporate Purposes		351.45	44.00	142.81	186.81	164.65	Refer Note 1	No comments received	No comments received
4	Issue Expenses		23.55	2.49	17.70	20.19	3.35	During the quarter, the company has spent ₹17.70 crores towards issue expenses.	No comments received	No comments received
Total			**1,500.00**	**1,086.49**	**245.51**	**1,332.00**	**168.00**			

*Chartered Accountant certificate from B. Naga Bhushan & Co dated October 22, 2026.

^A document dated October 23, 2026, presenting the utilization of funds certified by CFO, Mr. Sachin Ashok Salvi.

Note:

1. For utilisation towards General Corporate Purposes (GCP), the company transferred ₹84.81 crore from the Monitoring Agency Account to its current account and the remaining ₹58.00 crore as investments to the current accounts of its subsidiaries. These funds were subsequently utilised towards operational expenditures



through the respective current accounts. Since these current accounts are also used for routine business transactions, the monitoring proceeds have been commingled with the company's regular business funds.

(iii) Deployment of unutilized proceeds:

Sr. No.	Type of instrument and name of the entity invested in	Amount invested (Rs. crore)	Maturity date	Earning	Return on Investment (%)	Market Value as at the end of quarter
1	Money Market Fund – ICICI Prudential - Direct Growth	154.00	-	-	-	158.14
2	Liquid Fund – ICICI Prudential - Direct Growth	13.00	-	-	-	13.22
3	Monitoring agency account – Kotak Mahindra Bank	0.94	-	-	-	-
4	Escrow account – Kotak Mahindra Bank	0.06	-	-	-	-
	Total	**168.00**				

Note: As per the placement document, the unutilized net proceeds can be invested in one or more scheduled commercial banks included in the Second Schedule of the Reserve Bank of India Act, 1934 or temporarily invest the funds in creditworthy instruments, including money market / liquid mutual funds. Accordingly, ₹167.00 crore has been temporarily deployed in money market and liquid funds with ICICI Prudential Mutual Fund. The balance unutilized proceeds comprise ₹0.94 crore held in the Monitoring Agency Account and ₹0.06 crore in the Escrow Account, both maintained with Kotak Mahindra Bank. CARE Ratings has verified the mutual fund statements of ICICI Prudential Mutual Fund and the bank statements of Kotak Mahindra Bank as on September 30, 2026.

(iv) Delay in implementation of the object(s) – Not applicable

Objects	Completion Date		Delay (no. of days/ months)	Comments of the Board of Directors	
	As per the placement document	Actual		Reason of delay	Proposed course of action
Repayment and/or prepayment of certain outstanding borrowings, in full or part, availed by KIMS	March 31, 2027	Q1FY27	NA	No comments received	No comments received
Investment into certain Subsidiaries, namely Chalasani Hospitals Pvt Ltd, KIMS Hospitals Pvt Ltd and KIMS Hospital	March 31, 2027	Q2FY27	NA	No	No

Objects	Completion Date		Delay (no. of days/ months)	Comments of the Board of Directors	
	As per the placement document	Actual		Reason of delay	Proposed course of action
Bengaluru Pvt Ltd, for repayment or prepayment, in full or in part, of certain outstanding borrowings availed by such Subsidiaries				comments received	comments received
General Corporate Purposes	March 31, 2027	Ongoing	NA	No comments received	No comments received

5) Details of utilization of proceeds stated as General Corporate Purpose (GCP) amount in the placement document:

Sr. No	Item Head	Amount in Rs. Crore	Source of information / certifications considered by Monitoring Agency for preparation of report	Comments of Monitoring Agency	Comments of the Board of Directors
1	Salary payments of KIMS Limited	48.72	Bank statement, Confirmation from management, Chartered Accountant certificate	Note 1 & 2	No comments received
2	Investment in Saveera Institute of Medical Sciences Private Limited - Subsidiary	25.00			
3	Investment in KIMS Hospital Bengaluru Private Limited - Subsidiary	16.00			
4	Doctor payments of KIMS Limited	16.00			
5	Investment in KIMS Hospitals Private Limited – Subsidiary	15.00			
6	Vendor Payments	14.59			
7	TDS payments of KIMS Limited	5.50			
8	Investment in Chalasani Hospitals Private Limited - Subsidiary	2.00			
	Total	**142.81**			

Note:

1. For utilisation towards General Corporate Purposes (GCP), the company transferred ₹84.81 crore from the Monitoring Agency Account to its current account and the remaining ₹58.00 crore as investments to the current accounts of its subsidiaries. These funds were subsequently utilised towards operational expenditures through the respective current accounts. Since these current accounts are also used for routine business transactions, the monitoring proceeds have been commingled with the company's regular business funds.
2. Out of the ₹15.00 crore invested in the subsidiary, KIMS Hospitals Private Limited under GCP, ₹12.00 crore was utilised during Q2FY27, while the balance ₹3.00 crore is expected to be utilised during the subsequent quarter.

^ *Section from the offer document related to GCP:*
"The company proposes to deploy the balance Net Proceeds aggregating to ₹351.45 crore towards general corporate purposes, subject to such amount not exceeding 25% of the Issue Proceeds in accordance with the applicable law. The general corporate purposes for which our Company proposes to utilize the Net Proceeds include fulfilment of other financial commitments of Company or its subsidiaries, including payment of one or more debt financing agreements (other than in respect of the Objects as described), investments in subsidiaries (other than in respect of the Objects as described), other strategic initiatives, working capital requirements, business development activities, augmenting long-term cash resources, funding growth (organic or inorganic) opportunities, including acquisitions and meeting exigencies, meeting expenses, other expenditure considered expedient by our Company, as may be applicable and approved by our Board or a duly constituted committee thereof, from time to time."

Disclaimers to MA report:

a) This Report is prepared by CARE Ratings Ltd (hereinafter referred to as **"Monitoring Agency/MA"**). The MA has taken utmost care to ensure accuracy and objectivity while developing this Report based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever.

b) This Report has to be seen in its entirety; the selective review of portions of the Report may lead to inaccurate assessments. For the purpose of this Report, MA has relied upon the information provided by the management /officials/ consultants of the Issuer and third-party sources like statutory auditor/ internal auditor which is peer reviewed audit firm appointed by the Issuer believed by it to be accurate and reliable.

c) Nothing contained in this Report is capable or intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The MA is also not responsible for any errors in transmission and specifically states that it, or its directors, employees do not have any financial liabilities whatsoever to the users of this Report.

d) The MA and its affiliates do not act as a fiduciary. The MA and its affiliates also do not act as an expert to the extent defined under Section 2(38) of the Companies Act, 2013. While the MA has obtained information from sources it believes to be reliable, it does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives from statutory auditors/internal auditor which is peer reviewed audit firm (or from peer reviewed CA firms), lawyers, chartered engineers or other experts, and relies on in its reports.

e) The MA or its affiliates may have other commercial transactions with the entity to which the report pertains. As an example, the MA may rate the issuer or any debt instruments / facilities issued or proposed to be issued by the issuer that is subject matter of this report. The MA may receive separate compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors.



CARE Ratings Limited

401, Ashoka Scintilla, 3-6-520, Himayat Nagar,
Hyderabad - 500 029
Phone: +91-40-4010 2030

Corporate Office :4th Floor, Godrej Coliseum,
Somaiya Hospital Road, Off Eastern Express
Highway, Sion (E), Mumbai - 400 022
Phone: +91-22-6754 3456 • www.careedge.in